Skip to main content
ANIK
NASDAQ Industrial Applications And Services

Anika Therapeutics Reports Strong Q1 Results, Reaffirms Guidance, and Completes $15M Share Repurchase

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$15.26
Mkt Cap
$204.495M
52W Low
$7.87
52W High
$16.24
Market data snapshot near publication time

summarizeSummary

Anika Therapeutics reported robust first-quarter financial results, including double-digit revenue growth and significant gross margin expansion, while also completing a substantial $15 million share repurchase program.


check_boxKey Events

  • Strong Q1 Financial Performance

    Revenue grew 13% year-over-year to $29.6 million, with gross margin expanding to 64.2% (up 8 points) and Adjusted EBITDA reaching $4.3 million, compared to $0.1 million in the prior-year period.

  • 2026 Guidance Reaffirmed

    The company maintained its previously provided full-year revenue guidance of $114-$122.5 million and Adjusted EBITDA as a percent of revenue between 5% and 10%.

  • Significant Share Repurchase Completed

    Anika completed its previously announced $15 million 10b5-1 share repurchase program on April 10, 2026, at an average price of $10.76 per share.

  • Director Resignations

    Two directors, William R. Jellison and Glenn R. Larsen, Ph.D., notified the Board of their resignation, effective at the 2026 Annual Meeting. The company stated these departures did not involve any disagreement and were previously disclosed in the definitive proxy statement filed on April 28, 2026.


auto_awesomeAnalysis

Anika Therapeutics delivered a strong start to 2026, with revenue increasing 13% and gross margin improving by 8 points, leading to a substantial increase in Adjusted EBITDA. This operational strength, coupled with the completion of a $15 million share repurchase program, signals management's confidence and commitment to shareholder value. The reaffirmation of full-year guidance further reinforces a positive outlook. While two directors resigned, the company explicitly stated these departures were not due to any disagreements and were previously disclosed in the proxy statement, mitigating their impact. Investors should view these results as a positive indicator of the company's strategic transformation yielding improved profitability and efficiency.

At the time of this filing, ANIK was trading at $15.26 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $204.5M. The 52-week trading range was $7.87 to $16.24. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ANIK - Latest Insights

ANIK
Apr 29, 2026, 7:22 AM EDT
Source: Reuters
Importance Score:
8
ANIK
Apr 29, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
8
ANIK
Apr 28, 2026, 4:47 PM EDT
Filing Type: DEF 14A
Importance Score:
7
ANIK
Feb 26, 2026, 7:18 AM EST
Filing Type: 8-K
Importance Score:
8
ANIK
Jan 27, 2026, 7:29 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
ANIK
Jan 08, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
8